<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>431</serviceExecutionTime><Drug id="10454"><DrugName>rilonacept</DrugName><DrugNamesKey><Name id="42931910">Arcalyst</Name><Name id="42850910">rilonacept</Name></DrugNamesKey><DrugSynonyms><Name><Value>IL-1 Trap, Regeneron</Value></Name><Name><Value>rilonacept</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>IL-1 Trap</Value></Name><Name><Value>RGN-303</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Arcalyst</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19214">Regeneron Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="1123466">Kiniksa Pharmaceuticals Ltd</Company><Company id="1011051">Neovii Biotech GmbH</Company><Company id="19214">Regeneron Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10454" type="Drug"><TargetEntity id="298149" type="siDrug">Rilonacept</TargetEntity></SourceEntity><SourceEntity id="1011051" type="Company"><TargetEntity id="4295966349" type="organizationId">Neovii Biotech GmbH</TargetEntity></SourceEntity><SourceEntity id="1123466" type="Company"><TargetEntity id="5050920431" type="organizationId">Kiniksa Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="19214" type="Company"><TargetEntity id="4295907752" type="organizationId">Regeneron Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="136" type="ciIndication"><TargetEntity id="M10" type="ICD10"></TargetEntity><TargetEntity id="274" type="ICD9"></TargetEntity><TargetEntity id="10018627" type="MEDDRA"></TargetEntity><TargetEntity id="D006073" type="MeSH"></TargetEntity><TargetEntity id="-2021905547" type="omicsDisease"></TargetEntity><TargetEntity id="739" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1531" type="ciIndication"><TargetEntity id="10034484" type="MEDDRA"></TargetEntity><TargetEntity id="D010493" type="MeSH"></TargetEntity><TargetEntity id="-1310356195" type="omicsDisease"></TargetEntity><TargetEntity id="1972" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2887" type="ciIndication"><TargetEntity id="M35.3" type="ICD10"></TargetEntity><TargetEntity id="10036099" type="MEDDRA"></TargetEntity><TargetEntity id="D011111" type="MeSH"></TargetEntity><TargetEntity id="-120965901" type="omicsDisease"></TargetEntity><TargetEntity id="3634" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3003" type="ciIndication"><TargetEntity id="M08.0" type="ICD10"></TargetEntity><TargetEntity id="D001171" type="MeSH"></TargetEntity><TargetEntity id="-1334562803" type="omicsDisease"></TargetEntity><TargetEntity id="750" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3222" type="ciIndication"><TargetEntity id="10064569" type="MEDDRA"></TargetEntity><TargetEntity id="575" type="ORPHANET"></TargetEntity><TargetEntity id="1507" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3244" type="ciIndication"><TargetEntity id="10016207" type="MEDDRA"></TargetEntity><TargetEntity id="D010505" type="MeSH"></TargetEntity><TargetEntity id="342" type="ORPHANET"></TargetEntity><TargetEntity id="-1579159486" type="omicsDisease"></TargetEntity><TargetEntity id="1437" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3601" type="ciIndication"><TargetEntity id="10068850" type="MEDDRA"></TargetEntity><TargetEntity id="D056587" type="MeSH"></TargetEntity><TargetEntity id="208650" type="ORPHANET"></TargetEntity><TargetEntity id="-852827408" type="omicsDisease"></TargetEntity><TargetEntity id="2183" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3602" type="ciIndication"><TargetEntity id="10064570" type="MEDDRA"></TargetEntity><TargetEntity id="1503" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="12476" type="Action"><TargetEntity id="3407" type="Mechanism">Anti-IL-1alpha</TargetEntity><TargetEntity id="2050" type="Mechanism">IL-1alpha Production Inhibitors</TargetEntity></SourceEntity><SourceEntity id="12479" type="Action"><TargetEntity id="1559" type="Mechanism">Anti-IL-1beta</TargetEntity><TargetEntity id="873" type="Mechanism">IL-1beta Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-03142" type="ciTarget"><TargetEntity id="24826564035523" type="siTarget">Interleukin-1 alpha</TargetEntity><TargetEntity id="-1698036546" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-03143" type="ciTarget"><TargetEntity id="22280137135533" type="siTarget">Interleukin-1 beta</TargetEntity><TargetEntity id="391" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Cryopyrin associated periodic syndrome - US - Mar-2008</FirstLaunched><FirstLaunched>Familial cold autoinflammatory syndrome - US - Mar-2008</FirstLaunched><FirstLaunched>Muckle Wells syndrome - US - Mar-2008</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1531">Pericarditis</Indication><Indication id="3222">Muckle Wells syndrome</Indication><Indication id="3244">Familial mediterranean fever</Indication><Indication id="3600">Autoinflammatory disease</Indication><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><Indication id="3602">Familial cold autoinflammatory syndrome</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="136">Gout</Indication><Indication id="1626">Coronary atherosclerosis</Indication><Indication id="17">Anemia</Indication><Indication id="245">Osteoarthritis</Indication><Indication id="2887">Polymyalgia rheumatica</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="3003">Juvenile rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="12476">Interleukin-1 alpha ligand inhibitor</Action><Action id="12479">Interleukin-1 beta ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="84">Protein fusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="750">Freeze drying</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="898">Formulation powder</Technology></Technologies><EphmraCodes><Ephmra><Code>M4</Code><Name>ANTI-GOUT PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-06T06:00:41.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19214" linkType="Company"&gt;Regeneron&lt;/ulink&gt; has developed and launched rilonacept (Arcalyst; IL-1 Trap; RGN-303), a protein IL-1 alpha and beta antagonist, which acts as a high affinity ligand trap. The product is indicated in the US for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle Wells syndrome (MWS) in adults and children aged 12 years and older [&lt;ulink linkID="1121078" linkType="Reference"&gt;1121078&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In March 2008, the drug was launched in the US for CAPS, including FCAS and MWS [&lt;ulink linkID="888998" linkType="Reference"&gt;888998&lt;/ulink&gt;].  In October 2009, rilonacept was approved in the EU for CAPS, including FCAS and MWS  [&lt;ulink linkID="1052360" linkType="Reference"&gt;1052360&lt;/ulink&gt;], however by February 2013, the company had withdrawn the approved application for CAPS in the EU [&lt;ulink linkID="1393805" linkType="Reference"&gt;1393805&lt;/ulink&gt;] and the indication was presumed to be discontinued in the EU.  &lt;/para&gt;&lt;para&gt;Development is also ongoing in other indications, including cold contact urticaria and scleroderma. In June 2014, an investigator-sponsored,  phase II trial for cold contact urticaria was initiated; in January 2017, the trial was expected to complete in April 2018 [&lt;ulink linkID="1572919" linkType="Reference"&gt;1572919&lt;/ulink&gt;]. In December 2011, an investigator-sponsored,   phase I/II trial for scleroderma began; in March 2017, the trial was no longer recruiting and  expected to complete in  September 2017 [&lt;ulink linkID="1769145" linkType="Reference"&gt;1769145&lt;/ulink&gt;]. Regeneron is also investigating rilonacept for the potential treatment of familial Mediterranean fever and treatment of deficiency of interleukin-1 receptor antagonist (DIRA) [&lt;ulink linkID="1356657" linkType="Reference"&gt;1356657&lt;/ulink&gt;], [&lt;ulink linkID="1926124" linkType="Reference"&gt;1926124&lt;/ulink&gt;]. A pilot, investigator-led, phase II trial for DIRA began in February 2013 and completed in April 2016 [&lt;ulink linkID="1926138" linkType="Reference"&gt;1926138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="1123466" linkType="Company"&gt;Kiniksa Pharmaceuticals&lt;/ulink&gt; is also developing the drug for the potential treatment of recurrent pericarditis. In December 2018, a pivotal phase III clinical trial (RHAPSODY) in patients with recurrent pericarditis was initiated  [&lt;ulink linkID="2103245" linkType="Reference"&gt;2103245&lt;/ulink&gt;]; in March 2019, top-line data were expected in 2H20 [&lt;ulink linkID="2127142" linkType="Reference"&gt;2127142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Regeneron was  previously developing rilonacept for the treatment of rheumatoid arthritis (RA); however, in September 2005, the company discontinued development for this indication [&lt;ulink linkID="625107" linkType="Reference"&gt;625107&lt;/ulink&gt;]. &lt;ulink linkID="23137" linkType="Company"&gt;&lt;/ulink&gt;In November 2007,  a proof-of-concept study in anemia associated with chronic inflammation was initiated; however the study was terminated due to low enrollment   [&lt;ulink linkID="848292" linkType="Reference"&gt;848292&lt;/ulink&gt;]. The drug was also being developed for  atherosclerotic coronary artery disease, osteoarthritis, polymyalgia rheumatica and systemic onset juvenile idiopathic arthritis    [&lt;ulink linkID="625107" linkType="Reference"&gt;625107&lt;/ulink&gt;], [&lt;ulink linkID="769590" linkType="Reference"&gt;769590&lt;/ulink&gt;], [&lt;ulink linkID="645230" linkType="Reference"&gt;645230&lt;/ulink&gt;]; however, no development has been reported for these indications and by August 2010, they were not listed on Regeneron's pipeline [&lt;ulink linkID="1121107" linkType="Reference"&gt;1121107&lt;/ulink&gt;].  The company was also developing the drug for the potential treatment of gout flares (GFs) in patients who are initiating uric acid-lowering therapy. In November 2011, the FDA accepted an sBLA filing for the prevention of GFs in patients initiating uric acid-lowering therapy [&lt;ulink linkID="1242300" linkType="Reference"&gt;1242300&lt;/ulink&gt;]. In July 2012, the FDA issued a Complete Response Letter requesting additional clinical data and chemistry, manufacturing, and controls information relating to a proposed new dosage form  [&lt;ulink linkID="1311968" linkType="Reference"&gt;1311968&lt;/ulink&gt;]. In October 2012, the company reported that it discontinued the development of the drug for gout [&lt;ulink linkID="1334180" linkType="Reference"&gt;1334180&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2012, Regeneron stated that it expected patent coverage to expire between 2020 and 2028 [&lt;ulink linkID="1267527" linkType="Reference"&gt;1267527&lt;/ulink&gt;]. In February 2014, the company stated that the coverage included issued   manufacturing, various methods of use and pharmaceutical composition patents and pending applications covering the encoding DNA molecules and   proteins [&lt;ulink linkID="1528467" linkType="Reference"&gt;1528467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2002, Regeneron entered into an agreement with &lt;ulink linkID="14109" linkType="Company"&gt;Amgen&lt;/ulink&gt; and &lt;ulink linkID="14131" linkType="Company"&gt;Immunex&lt;/ulink&gt; for a nonexclusive license to certain intellectual property rights which could be used in the development and commercialization of rilonacept. Amgen and Immunex agreed to grant the license to Regeneron in connection with Amgen's pending acquisition of Immunex. The license to Regeneron was to become effective upon completion of the acquisition. Regeneron also has a license from &lt;ulink linkID="20449" linkType="Company"&gt;Tularik&lt;/ulink&gt; for the use of patents covering a receptor accessory protein used in rilonacept [&lt;ulink linkID="457329" linkType="reference"&gt;457329&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Cryopyrin-associated periodic syndromes&lt;/subtitle&gt;In January 2005, the drug received Orphan Drug designation for CAPS [&lt;ulink linkID="586377" linkType="Reference"&gt;586377&lt;/ulink&gt;]. In May 2006, the FDA awarded Fast Track status for CAPS [&lt;ulink linkID="803245" linkType="Reference"&gt;803245&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2007, the company completed submission of a rolling BLA  and requested a Priority Review [&lt;ulink linkID="803245" linkType="Reference"&gt;803245&lt;/ulink&gt;]. In August 2007, the BLA was accepted and granted a Priority Review [&lt;ulink linkID="820777" linkType="Reference"&gt;820777&lt;/ulink&gt;]. In November 2007, the FDA delayed its priority review of rilonacept  for CAPS after the company submitted supplementary chemistry, manufacturing and control information, as requested by the FDA in October 2007. The FDA extended the review as it considered the information to be a major amendment  [&lt;ulink linkID="846784" linkType="Reference"&gt;846784&lt;/ulink&gt;]. In February 2008, the drug was approved for CAPS  [&lt;ulink linkID="881077" linkType="Reference"&gt;881077&lt;/ulink&gt;], [&lt;ulink linkID="881089" linkType="Reference"&gt;881089&lt;/ulink&gt;]. In March 2008, the drug was launched in the US for CAPS, including FCAS and MWS [&lt;ulink linkID="888998" linkType="Reference"&gt;888998&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gout&lt;/subtitle&gt;In July 2011, Regeneron planned to file an sBLA with the FDA for the prevention of GFs in patients initiating uric acid-lowering therapy in 2H11 [&lt;ulink linkID="1210789" linkType="Reference"&gt;1210789&lt;/ulink&gt;]. In November 2011, the FDA accepted the filing of an sBLA for the prevention of GFs in patients initiating uric acid-lowering therapy; the PDUFA date was set as July 30, 2012 [&lt;ulink linkID="1242300" linkType="Reference"&gt;1242300&lt;/ulink&gt;]. However, in May 2012, the FDA Advisory Committee voted against approving the drug for preventing GFs [&lt;ulink linkID="1288611" linkType="Reference"&gt;1288611&lt;/ulink&gt;]. In July 2012, the FDA issued a Complete Response Letter requesting additional clinical data and CMC  information relating to a proposed new dosage form; at that time, Regeneron was reviewing the letter to determine the appropriate next steps [&lt;ulink linkID="1311968" linkType="Reference"&gt;1311968&lt;/ulink&gt;]. However, in October 2012, the company discontinued the development of the drug for gout [&lt;ulink linkID="1334180" linkType="Reference"&gt;1334180&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Arthritis&lt;/subtitle&gt;By May 2006, the drug also had Orphan status for systemic juvenile idiopathic arthritis [&lt;ulink linkID="670403" linkType="Reference"&gt;670403&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Familial Mediterranean fever&lt;/subtitle&gt;In January 2013, the drug was granted Orphan designation for the treatment of familial Mediterranean fever [&lt;ulink linkID="1356657" linkType="Reference"&gt;1356657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Deficiency of interleukin-1 receptor antagonist&lt;/subtitle&gt;In May 2017, the FDA granted rilonacept Orphan designation for the treatment of DIRA [&lt;ulink linkID="1926124" linkType="Reference"&gt;1926124&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2007, the EMEA's COMP adopted a positive opinion of the drug's application for European Orphan Drug designation for FCAS,  MWS and neonatal onset multisystem inflammatory disease (NOMID) [&lt;ulink linkID="801439" linkType="Reference"&gt;801439&lt;/ulink&gt;]. By August 2007, the EMEA had granted Orphans status for CAPS [&lt;ulink linkID="817982" linkType="Reference"&gt;817982&lt;/ulink&gt;]. In September 2009, the COMP of the EMEA recommended the drug be kept in the community registry of Orphan products [&lt;ulink linkID="1041285" linkType="Reference"&gt;1041285&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2008, an EU MAA had been filed under the centralized procedure for CAPS, including FCAS, MWS and NOMID [&lt;ulink linkID="943143" linkType="Reference"&gt;943143&lt;/ulink&gt;]. In July 2009, the CHMP of the EMEA recommended the drug for approval for CAPS in adults and children aged 12 years and above [&lt;ulink linkID="1028082" linkType="Reference"&gt;1028082&lt;/ulink&gt;], [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]. In October 2009, an MAA for CAPS including FCAS and MWS in adults and children over 12 years was approved under exceptional circumstances [&lt;ulink linkID="1052360" linkType="Reference"&gt;1052360&lt;/ulink&gt;]; by July 2012, the drug had not been launched in the EU [&lt;ulink linkID="1311968" linkType="Reference"&gt;1311968&lt;/ulink&gt;]. By February 2013, the company had withdrawn the approved application for CAPS in the EU [&lt;ulink linkID="1393805" linkType="Reference"&gt;1393805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2018, the product was granted "Clinically Urgent Foreign Drug" in China [&lt;ulink linkID="2089481" linkType="Reference"&gt;2089481&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cryopyrin-associated periodic syndromes&lt;/subtitle&gt;In June 2007, clinical data were presented at the Eighth EULAR meeting in Barcelona, Spain. Patients received rilonacept followed by a 9-week, double-blind, placebo-controlled, randomized withdrawal comparison. Patients randomized to placebo experienced a significant  return of disease activity, with a mean increase in symptom score of 0.94, versus  0.09 points for subjects who remained on rilonacept. Mean serum amyloid A (SAA) increased by 67.4 mg/l for placebo subjects, but remained unchanged for rilonacept-treated subjects. There were more injection site reactions (mostly mild) and upper respiratory tract infections (mild to moderate) with rilonacept. One subject withdrew due to a treatment-related adverse event. There were no drug-related serious adverse events [&lt;ulink linkID="807361" linkType="Reference"&gt;807361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, Regeneron announced that it had commenced a CAPS registration study in 4Q05. Patients would receive 160 mg/week of the drug in a 6-month double-blind, placebo-controlled, efficacy/safety arm, followed by a 6-month open-label safety arm [&lt;ulink linkID="645230" linkType="Reference"&gt;645230&lt;/ulink&gt;]. In October 2006, preliminary data were reported  from the trial which had enrolled patients with  FCAS and MWS. The primary endpoint of change in disease activity had been met. In the blinded arm of the study, patients taking rilonacept had an 85% reduction in symptoms, compared with a 13% reduction in the placebo group. In the rilonacept group, 70% of patients displayed at least a 75% reduction in their symptoms, compared with 0% of patients treated with placebo. Rilonacept treatment reduced the number of days with moderate or severe symptoms to 5%, compared to 50% prior to treatment. C-reactive protein and serum amyloid A levels were both reduced by 90%. In the 9-week washout period between the studies, patients in the placebo group had a five-fold increase in symptoms compared with the IL-1 trap group. No drug-related serious adverse events were reported. At that time, a 24-week extension arm was ongoing [&lt;ulink linkID="736254" linkType="Reference"&gt;736254&lt;/ulink&gt;], [&lt;ulink linkID="769097" linkType="Reference"&gt;769097&lt;/ulink&gt;]. In February 2007, further data from the 47-patient trial were reported at the American Academy of Allergy, Asthma and Immunology annual meeting in San Diego, CA. The results showed that the drug reduced CAPS symptoms and improved quality of life. A lasting, rapid, substantial reduction in clinical symptoms and signs, along with inflammation reduction and a favourable safety and tolerability profile was also observed [&lt;ulink linkID="606837" linkType="Reference"&gt;606837&lt;/ulink&gt;]. In June 2007, further data were presented at the Eighth EULAR meeting in Barcelona, Spain. Patients treated with 160 mg rilonacept experienced a mean decrease of 2.6 points (85%) in signs and symptoms score; scores for the subjects receiving placebo decreased only 0.3 points (13%). Disease activity decreased by &amp;gt; 30, &amp;gt; 50 or &amp;gt; 70% in 96, 87, and 70% of rilonacept-treated subjects versus 29, 8, and 0% in placebo treated subjects, respectively. Rilonacept significantly decreased mean SAA levels by 54.5 mg/l (-93%), versus -0.08 (0%) for placebo  [&lt;ulink linkID="807361" linkType="Reference"&gt;807361&lt;/ulink&gt;]. In November 2007, extended safety results from a phase III CAPS trial  were presented at the 71st American College of Rheumatology annual meeting in Boston, MA [&lt;ulink linkID="880542" linkType="Reference"&gt;880542&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In the fourth quarter of 2004, an exploratory CAPS trial was initiated; in February 2005, results from the trial were expected later in 2005 [&lt;ulink linkID="586377" linkType="Reference"&gt;586377&lt;/ulink&gt;]. According to results reported in June 2005, IL-1 Trap improved CAPS in four patients with syndromes from the CAPS family of autoinflammatory diseases. In the ongoing pilot study, conducted under a CRADA from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, patients received a sc loading dose of 100 mg per day for 3 days. They were then evaluated and, after the return of signs and symptoms, were entered into an extension phase with once-weekly IL-1 Trap dosing. All four patients were adults with FCAS or FCAS-MWS overlap syndrome. IL-1 Trap reduced daily patient diary scores and acute phase reactant levels in  all patients. The return of signs and symptoms occurred in all patients at a median of 21 days (range 9-26), but, upon resumption of dosing, all four patients maintained favorable responses. No significant adverse events or injection site reactions had occurred [&lt;ulink linkID="606837" linkType="Reference"&gt;606837&lt;/ulink&gt;]. Similar results were presented in January 2006 at JP Morgan's 24th Annual Healthcare Conference in San Francisco, CA [&lt;ulink linkID="645230" linkType="Reference"&gt;645230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gout&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In November 2012, data from a numbers needed to treat to benefit (NNTB) analyses from PRESURGE-I and PRESURGE-II were presented at the ACR/ARHP Annual Meeting in Washington DC. It was shown that around 50% of patients starting urate-lowering therapy would benefit from treatment with rilonacept (NNTB = around 2). Patients would experience about 1.6 fewer GFs with treatment [&lt;ulink linkID="1341977" linkType="Reference"&gt;1341977&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2011, a multicenter, randomized, double-blind, parallel-group, phase III study (&lt;ulink linkID="81827" linkType="Protocol"&gt;NCT01459796&lt;/ulink&gt;; IL1T-GA-1101; UPSURGE) began in the US to assess the long-term safety and efficacy of rilonacept for the prevention of GFs in patients with gout beginning allopurinol therapy (expected n = 350). The primary endpoint was safety. The study was expected to complete in  June 2013 [&lt;ulink linkID="1310816" linkType="Reference"&gt;1310816&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, data were presented from a pooled sub-analysis from three phase III, randomized, double-blind, placebo-controlled trials (PRE-SURGE 1, PRE-SURGE 2, and RE-SURGE) of rilonacept (80 and 160 mg sc) at the ACR/ARHP Annual Meeting in Chicago, IL. Patients (n = 841) with tophi and/or polyarticular disease who initiate uric acid-lowering therapy were included. Patients with tophi and/or polyarticular disease had significantly higher rates of GFs when compared with monoarticular, non-tophaceous disease patients, and among these patients, rilonacept reduced the mean number of GFs per patient significantly. In patients with risk factors for GFs, 80 and 160 mg rilonacept-treatment resulted in a 69.5 and 67.7% reduction in the mean number of GFs per patient, when compared with placebo. Of the population with risk factors, 29.8 and 30.7% in the 80 and 160 mg rilonacept groups had &amp;gt;/= 1 GF, compared with 59.4% of patients in the placebo group (almost a 50% reduction with rilonacept) [&lt;ulink linkID="1228667" linkType="Reference"&gt;1228667&lt;/ulink&gt;]. In November 2012,   further  data  were presented at the ACR/ARHP Annual Meeting in Washington, DC. In CKD patients from PRESURGE-1 and -2 trials, the GF/patient was reduced by 33 and 53% in the 80-mg (n = 21) and 160-mg (n = 19) groups, respectively. In CKD patients from RESURGE study, the GF/patient was reduced by 65%. Analysis of data pooled from all the trials showed a consistent effect of rilonacept. In placebo (n = 306), 80-mg (n = 162), and 160-mg (n = 585) groups, the mean GF/patient were 1.65, 0.51, and 0.50, respectively [&lt;ulink linkID="1342532" linkType="Reference"&gt;1342532&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a multinational, randomized, placebo-controlled, double-blind, parallel group phase III study (&lt;ulink linkID="59592" linkType="Protocol"&gt;NCT00958438&lt;/ulink&gt;; IL1T-GA-0816; PRE-SURGE 2) began, to assess the safety and efficacy of rilonacept in patients with gout (n = 244). Patients were dosed with a 160 mg sc loading dose then 80 mg/2 ml sc weekly for 16 weeks, or 320 mg initially then 160 mg/2 ml weekly. The primary endpoint was the number of GFs during the treatment period. The study was completed in December 2010 [&lt;ulink linkID="1121202" linkType="Reference"&gt;1121202&lt;/ulink&gt;]. In February 2011, data showed that rilonacept had met its primary and all secondary endpoints in the PRE-SURGE 2 trial.  Patients receiving rilonacept demonstrated a 72% decrease in the mean number of GFs compared with placebo.  Rilonacept  reduced the  proportion of patients experiencing at  least one GF  by 63% (160 mg dose) and 54% (80 mg dose), and reduced the number of patients experiencing two  or more flares by 82% (160 mg dose) and 74% (80 mg dose).  Rilonacept was well tolerated  relative to placebo and injection site reactions were mild [&lt;ulink linkID="1171385" linkType="Reference"&gt;1171385&lt;/ulink&gt;].  In May 2011, similar results were  presented at EULAR 2011 in London, UK [&lt;ulink linkID="1194507" linkType="Reference"&gt;1194507&lt;/ulink&gt;]. In November 2011, data were presented at the ACR/ARHP Annual Meeting in Chicago, IL. The mean reductions in the flare rate was 68.1% with the 160-mg dose, and 58.9% with the 80-mg dose [&lt;ulink linkID="1231317" linkType="Reference"&gt;1231317&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, the US multicenter, randomized, active-controlled, double-blind phase III SURGE trial (&lt;ulink linkID="47991" linkType="Protocol"&gt;NCT00855920&lt;/ulink&gt;; IL1T-GA-0814) was initiated in patients (n = 225) experiencing acute gout attacks. The study would assess pain during the initial 72 h of treatment. A total of 225 patients would receive 320 mg of rilonacept via injection on day 1 followed by oral placebo for 12 days, 320 mg of iv rilonacept on day 1 plus oral indomethacin for 12 days or placebo on day 1 followed by oral indomethacin for 12 days. The trial was completed in February 2010  [&lt;ulink linkID="994731" linkType="Reference"&gt;994731&lt;/ulink&gt;], [&lt;ulink linkID="1242540" linkType="Reference"&gt;1242540&lt;/ulink&gt;]. In June 2010, data from the SURGE trial were reported demonstrating there to be no significant benefit from the indomethacin plus rilonacept combination. Subjects treated with indomethacin alone had an average reduction of 1.55 points from baseline on the Likert scale, those on indomethacin plus rilonacept had an average reduction of 1.55 points, and those on rilonacept alone experienced an average reduction of just 0.69 points. The drug was well tolerated [&lt;ulink linkID="1106876" linkType="Reference"&gt;1106876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, the multinational, randomized, placebo-controlled, double-blind phase III RE-SURGE trial (&lt;ulink linkID="47999" linkType="Protocol"&gt;NCT00856206&lt;/ulink&gt;; IL1T-GA-0815) was initiated. The global study would assess the safety of rilonacept compared with placebo over 16 weeks in patients (n = 1274) who were at risk of GFs due to their urate-lowering drug treatment. A total of 300 patients would be treated with placebo and 900 would receive a 320 mg initial loading dose of rilonacept followed by weekly 160 mg injections. The trial was completed in January 2011 [&lt;ulink linkID="994731" linkType="Reference"&gt;994731&lt;/ulink&gt;], [&lt;ulink linkID="1242530" linkType="Reference"&gt;1242530&lt;/ulink&gt;]. In February 2011, data from the trial were reported; rilonacept was generally well tolerated with a safety profile consistent with PRE-SURGE 1 and 2 trials. Other than injection site reactions, which were usually mild (in 15.2% of rilonacept treated patients vs 3.3% in placebo-treated patients), treatment-emergent adverse events were balanced between   patients receiving rilonacept or placebo.  Cumulative infection rate was 20.1% in rilonacept -treated patients vs 19.1% in placebo-treated patients, serious infections were reported in 0.5% of rilonacept-treated patients vs 0.9% of placebo-treated patients, and deaths were reported in 0.3% of rilonacept-treated patients vs 0.9% of placebo patients. The secondary endpoint of efficacy was also achieved [&lt;ulink linkID="1171385" linkType="Reference"&gt;1171385&lt;/ulink&gt;]. In November 2011, further data were presented at the ACR/ARHP Annual Meeting in Chicago, IL. Of the patients who received weekly sc injections of rilonacept (160 mg; n = 985) or placebo (n = 330), the mean number of total GFs per patient decreased by 70.3% in the rilonacept group at week 16 when compared with placebo (0.51 versus 1.73). Rilonacept-treatment also resulted in a 49.6% reduction in patients experiencing &amp;gt;/= 1 GFs. In the rilonacept group, 11.7% of patients experienced &amp;gt;/= 2 GFs (66.4% reduction), compared with 34.7% of patients in the placebo group [&lt;ulink linkID="1228660" linkType="Reference"&gt;1228660&lt;/ulink&gt;], [&lt;ulink linkID="1231317" linkType="Reference"&gt;1231317&lt;/ulink&gt;]. At that time, further data were presented from the same conference. In all the subgroups, the efficacy of rilonacept similar to that observed in the total population. Across the subgroups, reductions in GFs per patient were in the range of 67.8 to 72.3%, reductions in GF days per patient were in the range of 58.7 to 69.4%, reduction in the proportion of patients with &amp;gt;/= 1 GFs were in the range of 44.7 to 52.4% and that of patients with &amp;gt;/= 2 GFs were in the range of 60.4 to 84.3% [&lt;ulink linkID="1231320" linkType="Reference"&gt;1231320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase III study (&lt;ulink linkID="50031" linkType="Protocol"&gt;NCT00829829&lt;/ulink&gt;; IL1T-GA-0810; PRE-SURGE 1) began in the US and Canada to assess the safety and efficacy of rilonacept in patients with gout (n = 241). Patients were dosed with a 160 mg sc loading dose then 80 mg/2 ml sc weekly for 16 weeks, or 320 mg initially then 160 mg/2 ml weekly. The primary endpoint was the number of GFs during the treatment period. The study completed in June 2010  [&lt;ulink linkID="1121203" linkType="Reference"&gt;1121203&lt;/ulink&gt;]. In June 2010, data from PRE-SURGE 1 were reported. The primary endpoint was met with an 80 and 73% decrease in the mean number of GFs compared with placebo in the 160 and 80 mg dose groups, respectively. Secondary endpoints were also met with an 88 and 65% reduction in the proportion of patients experiencing two or more flares or at least one GF, respectively. The drug was well tolerated with no serious drug-related adverse events [&lt;ulink linkID="1106876" linkType="Reference"&gt;1106876&lt;/ulink&gt;]. In January 2011, similar data were presented at the 29th Annual JPMorgan Healthcare Conferences in San Francisco, CA. At this time, further phase III data were expected to be reported in Q1 2011 [&lt;ulink linkID="1160626" linkType="Reference"&gt;1160626&lt;/ulink&gt;]. In May 2011, similar clinical data were presented at EULAR 2011 in London, UK [&lt;ulink linkID="1193641" linkType="Reference"&gt;1193641&lt;/ulink&gt;]. In November 2011, data were presented at the ACR/ARHP Annual Meeting in Chicago, IL. The mean reductions in the flare rate was 76.9% with the 160-mg dose, and 66.4% with the 80-mg dose [&lt;ulink linkID="1231317" linkType="Reference"&gt;1231317&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2007, a phase II trial for the prevention of GFs induced by the initiation of uric acid-lowering drug therapy was  initiated [&lt;ulink linkID="829048" linkType="Reference"&gt;829048&lt;/ulink&gt;]. In September 2008, positive results were reported. In the double-blind, placebo-controlled study (&lt;ulink linkID="30212" linkType="Protocol"&gt;NCT00610363&lt;/ulink&gt;; IL1T-GA-0619), 83 gout patients on allopurinol received an initial 320 mg dose of rilonacept, followed by weekly doses of 160 mg. The mean number of flares per patient over the first 12 weeks was 0.15 for the rilonacept group, compared with 0.79 for placebo, meeting the primary endpoint. All secondary endpoints  were also met. In the first 12 weeks of treatment, 45.2% of patients receiving placebo experienced a GF, 47.4% of which had more than one flare. In the rilonacept group, 14.6% of patients experienced a GF and none had more than one flare. No serious drug-related adverse events were reported [&lt;ulink linkID="940223" linkType="Reference"&gt;940223&lt;/ulink&gt;], [&lt;ulink linkID="1252468" linkType="Reference"&gt;1252468&lt;/ulink&gt;]. In January 2012, similar data were published  [&lt;ulink linkID="1252453" linkType="Reference"&gt;1252453&lt;/ulink&gt;], [&lt;ulink linkID="1252469" linkType="Reference"&gt;1252469&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;By February 2007, preclinical studies had been completed and a proof-of -concept study was underway  [&lt;ulink linkID="769947" linkType="Reference"&gt;769947&lt;/ulink&gt;]. In September 2007, a single-blind, placebo run-in-controlled, 6-week,  study showed that    in 10 patients, the mean patients' pain scores were  reduced by 41 and 56% during the first 2 and 6 weeks of  treatment with rilonacept respectively, compared with 13% for placebo in the first 2 weeks. The drug was well tolerated  and  with mild injection-site reaction being the only reported side effect [&lt;ulink linkID="829048" linkType="Reference"&gt;829048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Arthritis&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2004, clinical data on rilonacept were presented at the Eight annual IBC Drug Discovery Technology Europe congress, London, UK. In an 82-patient study, rilonacept was well tolerated at doses of up to 80 microg/kg for 6 weeks, with a terminal half-life of 5 to 9 days [&lt;ulink linkID="527458" linkType="reference"&gt;527458&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2004, a phase IIb trial was expected to begin in the second half of 2004 following completion of the development of a new formulation and patient tolerability studies [&lt;ulink linkID="525146" linkType="reference"&gt;525146&lt;/ulink&gt;]. Subjects in the worldwide trial were to receive placebo, or 160 or 320 mg drug per week, for 24 weeks [&lt;ulink linkID="616163" linkType="Reference"&gt;616163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2002, Regeneron commenced a 12-week, dose-ranging phase II trial to study the safety and efficacy of rilonacept in patients with active RA, who had an inadequate response to at least one disease-modifying antirheumatic medicine. The study was to involve approximately 200 participants, receiving self-administered, weekly sc injections (25, 50 or 100 mg rilonacept) [&lt;ulink linkID="459031" linkType="reference"&gt;459031&lt;/ulink&gt;]. In January 2003, results from this trial were expected around the middle of that year [&lt;ulink linkID="476363" linkType="reference"&gt;476363&lt;/ulink&gt;]. In October 2003, Regeneron reported the results of the trial, which showed that the treatment was effective at the highest dose used. In addition, the drug was safe and well tolerated. The multicenter phase II trial was a randomized, placebo-controlled, double-blind study in 200 patients with active RA, who had an inadequate response to at least one disease-modifying antirheumatic drug (DMARDs). The patients received weekly sc injections of 25, 50, or 100 mg of rilonacept or placebo. A substantial proportion of the subjects in each group were on DMARDs at baseline and continued their treatment throughout the trial (65%, 63%, 60%, and 68% of patients in the placebo, 25 mg, 50 mg, and 100 mg groups, respectively). The treatment period ran for 12 weeks and patients were evaluated for safety and to track disease progression for 10 weeks following treatment cessation. The American College of Rheumatology (ACR20) criteria for improvement in RA was the primary efficacy endpoint. ACR50, ACR70, and ACR-N scores and other measures of disease activity were evaluated as secondary efficacy and exploratory endpoints. Patients treated with the 100 mg dose of rilonacept exhibited improvements in primary and secondary endpoints of the trial. When compared with placebo, these patients showed increases in: the proportion of ACR20 responses (46% versus 30.9%); the average ACR-N Score (24.1% versus 13.5%); the proportion of ACR50 and ACR70 responses (20% versus 9.1%; 12.0 % versus 3.6%, respectively); a greater decrease in the disease activity score (-1.1 versus -0.7); and a faster time of onset of ACR20 response (median time to onset of 36 days versus 77 days) [&lt;ulink linkID="507903" linkType="reference"&gt;507903&lt;/ulink&gt;]. Similar data were presented in June 2004, at the EULAR 2004 meeting in Berlin, Germany. Treatment with the highest dose also showed a rapid significant decrease in erythrocyte sedimentation rate and C-reactive protein levels, and an improvement in disease activity score 28 responses [&lt;ulink linkID="546527" linkType="reference"&gt;546527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2006, data from a double-blind, placebo-controlled phase I trial in 11 patients with systemic juvenile idiopathic arthritis (SJIA) aged five to 18 years were presented at the 70th ACR Annual Meeting in Washington DC. After a 4-week blinded study period, all patients received IL-1 TRAP (2.2 mg/kg) weekly up to 4 weeks in the open label extension study. IL-1 TRAP was well tolerated and was efficacious after a 4-week treatment period. In five out of 11 patients who had previously shown an inadequate response to anakinra, IL-1 TRAP was also efficacious [&lt;ulink linkID="747041" linkType="Reference"&gt;747041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2002, Regeneron revealed positive preliminary results from a phase Ib trial of rilonacept in RA [&lt;ulink linkID="435060" linkType="reference"&gt;435060&lt;/ulink&gt;], [&lt;ulink linkID="450049" linkType="reference"&gt;450049&lt;/ulink&gt;]. Similar positive preliminary phase I trial data were presented at the American College of Rheumatology conference in San Francisco, CA in November 2001, and in April 2003, at SMi's Anti-Arthritic Agents meeting in London, UK [&lt;ulink linkID="488243" linkType="reference"&gt;488243&lt;/ulink&gt;], [&lt;ulink linkID="488565" linkType="reference"&gt;488565&lt;/ulink&gt;]. Rilonacept was generally well tolerated and displayed a favorable safety profile. No drug-related serious adverse events were reported. Rilonacept also displayed positive pharmacological properties. After 6 weeks of treatment and 4 weeks of follow-up, no antibodies were detected in reaction to rilonacept [&lt;ulink linkID="429356" linkType="reference"&gt;429356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, Regeneron initiated a placebo-controlled, double-blind, dose-escalation phase I trial of rilonacept to assess safety and tolerability in patients with RA. The trial was to be conducted at seven centers in the US [&lt;ulink linkID="394203" linkType="reference"&gt;394203&lt;/ulink&gt;]. By May 2001, single-dose and multiple-dose phases were ongoing, with results expected in the second half of 2001 [&lt;ulink linkID="407756" linkType="reference"&gt;407756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Coronary atherosclerosis&lt;/subtitle&gt;In December 2006, a randomized, double-blind, placebo control, parallel assignment, safety/efficacy phase II US trial (NCT00417417;  070055; 07-H-0055) was initiated in patients (expected n = 60)  with atherosclerotic coronary artery disease. The  primary endpoint  of the study was to examine the effects of rilonacept on C-reactive protein levels and the secondary endpoints included endothelial progenitor cell mobilization and endothelial function. Patient recruitment was ongoing in March 2007 [&lt;ulink linkID="769590" linkType="Reference"&gt;769590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Urticaria&lt;/subtitle&gt;In June 2014, an investigator-sponsored,   double-blind, randomized, placebo-controlled, single-center, parallel-assigned, phase II trial (&lt;ulink linkID="199388" linkType="Protocol"&gt;NCT02171416&lt;/ulink&gt;; Cures, 2012-005726-30) was recruiting in Germany to evaluate the safety and efficacy of rilonacept in patients (expected n = 20) with cold contact urticaria. In January 2017, the trial was expected to complete in April 2018 [&lt;ulink linkID="1572919" linkType="Reference"&gt;1572919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic Kidney Disease&lt;/subtitle&gt;In November 2015, clinical data from a two-site, double-blind study in 42 patients with moderate to severe chronic kidney diseases were presented at ASN's Kidney Week 2015 in San Diego, CA. Rilonacept reduced systemic inflammation effectively. No change in serum calcium, phosphorus, 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, intact parathyroid hormone and intact FGF23 levels were observed with IL-1 inhibition [&lt;ulink linkID="1708510" linkType="Reference"&gt;1708510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Scleroderma&lt;/subtitle&gt;In December 2011, an investigator-sponsored,    randomized, double-blind, single-group assignment, phase I/II trial (&lt;ulink linkID="85144" linkType="Protocol"&gt;NCT01538719&lt;/ulink&gt;; H31332) began in the US in patients (n = 19) with scleroderma. The primary endpoint of the trial was to evaluate over 5 years the effect of rilonacept on the expression of a four-gene biomarker in the skin. In March 2017, the trial was active,  and recruitment  was complete; at that time, the trial was expected to complete in  September 2017 [&lt;ulink linkID="1769145" linkType="Reference"&gt;1769145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Deficiency of interleukin-1 receptor antagonist&lt;/subtitle&gt;In February 2013, an investigator-led, non-randomized, open-label, phase II trial (&lt;ulink linkID="112984" linkType="Protocol"&gt;NCT01801449&lt;/ulink&gt;; 130086; 13-AR-0086) was initiated by &lt;ulink linkID="1034431" linkType="Company"&gt;National Institute of Arthritis and Musculoskeletal and Skin Diseases&lt;/ulink&gt; (NIAMS) to study the safety and effectiveness of rilonacept for children and adults in the US with DIRA (n= 6). The trial completed in April 2016 [&lt;ulink linkID="1926138" linkType="Reference"&gt;1926138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pericarditis&lt;/subtitle&gt;In August 2018, a double-blind, placebo-controlled, randomized-withdrawal design pivotal phase III clinical trial (RHAPSODY) in patients (n = 60) with recurrent pericarditis was planned to be initiated in the US in the second half of 2018 [&lt;ulink linkID="2060438" linkType="Reference"&gt;2060438&lt;/ulink&gt;]. In November 2018, the global, multicenter trial (&lt;ulink linkID="359507" linkType="Protocol"&gt;NCT03737110&lt;/ulink&gt;; KPL-914-C002; 2018-002719-87) was planned to commence in December 2018 in patients (expected n = 56) with recurrent pericarditis. The primary endpoint was the time to first pericarditis recurrence up to 24 weeks. At that time, the study was expected to complete in June 2021 [&lt;ulink linkID="2103479" linkType="Reference"&gt;2103479&lt;/ulink&gt;]. In December 2018, the trial was initiated and was recruiting participants [&lt;ulink linkID="2103245" linkType="Reference"&gt;2103245&lt;/ulink&gt;]. In March 2019, top-line data were expected in 2H20 [&lt;ulink linkID="2127142" linkType="Reference"&gt;2127142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2018, an open-label, proof-of-concept, phase II trial was underway to assess rilonacept in subgroups of patients with pericarditis. At that time, four patients had been enrolled and three patients showed a reduction in C-reactive protein and a reduction in scores of an 11-point Numerical Rating Scale instrument for assessing pericardial-associated chest pain, in the first week of treatment [&lt;ulink linkID="2046748" linkType="Reference"&gt;2046748&lt;/ulink&gt;]. In November 2018, the company planned to report additional data and close enrollment    "later that year" [&lt;ulink linkID="2089670" linkType="Reference"&gt;2089670&lt;/ulink&gt;]. By November 2018, 12 patients had been enrolled. At that time, results were reported showing a reduction in both inflammation and reported pain after the initial dose. Mean patient-reported pericardial pain on an 11-point numerical rating scale (NRS)  decreased from a baseline score of 4.6 to 0.9 at week 6, while the mean CRP level  decreased from 4.9 mg/dl at baseline to 0.37 mg/dl at week 6. The median time to CRP level normalization was 9 days and at 6 weeks, pericardial signs had resolved, including pericardial effusion, PR segment depression, widespread ST elevation, and pericardial rub. Continued clinical response was demonstrated in patients who received treatment for a total of 24 weeks;  mean patient-reported pericardial pain NRS scoring  further decreased to 0.3, while mean CRP level was 0.44 mg/dl at 24 weeks; the pericardial effusion in the 1 remaining subject resolved during the extension period; and of the 4 subjects on corticosteroids at baseline, the 1 subject who  completed 24 weeks of treatment successfully tapered off corticosteroids [&lt;ulink linkID="2103245" linkType="Reference"&gt;2103245&lt;/ulink&gt;]. In December 2018, enrollment was completed [&lt;ulink linkID="2127142" linkType="Reference"&gt;2127142&lt;/ulink&gt;]. In March 2019, further similar interim data were reported at the American College of Cardiology's (ACC) 68th Annual Scientific Session in New Orleans, LA; 25 patients enrolled in the 6-week base treatment period across, 23 patients continued into the optional 18-week extension period and 11 completed 24 weeks of treatment. Of 12 patients with symptomatic recurrent pericarditis (CRP &amp;gt; 1mg/dl), 7 completed 24 weeks of treatment and experienced a further decline in  patient-reported pericardial pain on an 11-point NRS to 0.4 mg/dl (mean CRP was 0.3 mg/dl at 24 weeks). Patients with symptomatic recurrent pericarditis and CRP &amp;lt;/= 1 mg/dl, with asymptomatic steroid-dependent recurrent pericarditis, with symptomatic post-pericardiotomy syndrome (PPS) and asymptomatic steroid-dependent PPS also showed reductions in both inflammation and reported pain. At that time, the trial was expected to complete in 2H19 [&lt;ulink linkID="2130921" linkType="Reference"&gt;2130921&lt;/ulink&gt;]. Further data were presented at the same conference. Adverse events were reported in 13 patients; 9 were drug-related. Mild transient injection site reactions were the most commonly reported. No discontinuations reported [&lt;ulink linkID="2137023" linkType="Reference"&gt;2137023&lt;/ulink&gt;]. In March 2019, the trial was expected to complete in the second half of 2019 [&lt;ulink linkID="2147780" linkType="Reference"&gt;2147780&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2002, data on rilonacept were presented at the 3rd SMi meeting on Advances in Anti-Arthritic Agents in London, UK. The drug bound IL-1beta with extremely high affinity (Kd = 1.5 pM) and inhibited IL-1-induced IL-6 release with similar potency (IC50 = 4pM). Rilonacept was effective at a dose of 20 mg/kg inhibiting IL-1-induced IL-6 release in mice. A murine form of the compound almost completely blocked collagen-induced arthritis [&lt;ulink linkID="450049" linkType="reference"&gt;450049&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2014, Regeneron stated that it  used third parties to supply  raw materials and other products for the manufacture and formulation of  rilonacept.  At that time, it was increasing its own manufacturing capacity with the construction of additional manufacturing space in  Rensselaer, US, and intended  to  rely on corporate collaborators and contract manufacturers to produce commercial quantities of the drug in the future. The acquisition of an additional manufacturing facility in Limerick, Ireland, had reached a preliminary agreement   [&lt;ulink linkID="1528467" linkType="Reference"&gt;1528467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2002,  Regeneron entered into an agreement with &lt;ulink linkID="18624" linkType="Company"&gt;ZymoGenetics&lt;/ulink&gt; to use Ig-fusion protein technology that could be incorporated into its existing Trap programs, including rilonacept [&lt;ulink linkID="454136" linkType="Reference"&gt;454136&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Cem Gabay, Division of Rheumatology, &lt;ulink linkType="Company" linkID="21063"&gt;University Hospital&lt;/ulink&gt; of Geneva, 26 Avenue Beau-Sejour, 1211 Geneva 14, Switzerland. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 04 February 2003&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 28 February 2003&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, affecting approximately 1% of the Caucasian population. RA is characterized by the presence of chronic joint inflammation and subsequent tissue destruction associated with increased disability. In addition, the results of epidemiological studies have demonstrated that RA is associated with increased mortality [&lt;ulink linkType="reference" linkID="478748"&gt;478748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Interleukin (IL)-1 plays a major role in a variety of inflammatory processes and is important in the pathophysiology of RA. IL-1 is expressed in the rheumatoid synovium and its levels are elevated in the synovial fluid [&lt;ulink linkType="reference" linkID="202083"&gt;202083&lt;/ulink&gt;]. It stimulates the recruitment of inflammatory cells within the rheumatoid joints and exerts a strong catabolic effect on articular cartilage by decreasing the synthesis of proteoglycans and type II collagen while increasing the production of matrix metalloproteases [&lt;ulink linkType="reference" linkID="202083"&gt;202083&lt;/ulink&gt;]. These effects of IL-1 contribute to the progression of joint damage in RA. IL-1 is also involved in other articular diseases such as osteoarthritis [&lt;ulink linkType="reference" linkID="478755"&gt;478755&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;IL-1 includes two different cytokines, IL-1alpha and IL-1beta, which are produced from two different genes and are synthesized as proteins of 31 kDa (pre-IL-1alpha and pre-IL-1beta). Pre-IL-1beta is cleaved by IL-1beta converting enzyme (ICE or caspase-1) to generate mature 17-kDa IL-1beta. In contrast, IL-1alpha is a cell-associated cytokine. Upon binding to IL-1 receptors, both IL-1alpha and IL-1beta induce similar effects [&lt;ulink linkType="reference" linkID="266429"&gt;266429&lt;/ulink&gt;]. The main difference between these cytokines is that only mature IL-1beta is biologically active, whereas both pre-IL-1alpha and IL-1alpha can bind IL-1 receptors [&lt;ulink linkType="reference" linkID="266429"&gt;266429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;IL-1 has three receptors that are expressed either as cell surface proteins or as soluble receptors. IL-1 receptor type I (IL-1RI) and IL-1 receptor accessory protein (IL-1RacP) bind IL-1 and are responsible for intracellular signals. IL-1 receptor type II (IL-1RII) has a short cytoplasmic domain and acts as a decoy receptor. The IL-1 receptor antagonist (IL-1ra) is a member of the IL-1 family that has structural homologies with IL-1 and can bind to IL-1RI, but does not induce any intracellular response. Instead, IL-1ra prevents the interaction of IL-1 with its cell surface receptors and thus, acts as a natural IL-1 inhibitor. The administration of &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;, a recombinant form of IL-1ra in various experimental models of arthritis improved articular inflammation and the clinical parameters of disease activity, preventing the progression of radiological signs of joint damage in RA patients. The use of IL-1ra also had a chondroprotective effect in different experimental models of osteoarthritis. Amgen has launched &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; for the treatment of RA in combination with methotrexate. Taken together, these results provide a strong foundation for development of different strategies aimed at blocking the effects of IL-1 in arthritis [&lt;ulink linkType="reference" linkID="454821"&gt;454821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Besides &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;, other IL-1 inhibitors include soluble IL-1RII, which binds to IL-1beta and blocks its interactions with membrane-bound receptors, ICE inhibitors that inhibit the extracellular release of IL-1beta, and different inhibitors blocking IL-1-induced intracellular signals. The use of soluble IL-1RII and signaling inhibitors (nuclear factor-kappaB and c-jun N-terminal kinase inhibitors) has proven to be of potential value in experimental models of RA. However, no data are available in humans. &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="20739"&gt;Vertex Pharmaceuticals Inc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="27254"&gt;Aventis SA&lt;/ulink&gt;) is an ICE inhibitor that has shown efficacy in animal models of RA and was well-tolerated in a phase I clinical trial. However, in a phase II clinical trial, &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; did not differ significantly from the placebo group [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;]. This disappointing result can be explained by the fact that, besides ICE, other enzymes are also able to cleave pre-IL-1beta and thus contribute to the release of biologically active IL-1beta. In addition, ICE does not influence the biological effects of IL-1alpha.&lt;/para&gt;&lt;para&gt;IL-1 trap is a novel approach to the treatment of RA. It is a fusion protein containing some of the extracellular binding motifs of IL-1RI and IL-1RacP coupled to the Fc fraction of human IgG [&lt;ulink linkType="reference" linkID="478752"&gt;478752&lt;/ulink&gt;]. IL-1 trap binds IL-1 with high affinity and blocks its biological effects [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;], and results from animal studies and clinical trials in RA patients are encouraging [&lt;ulink linkType="reference" linkID="450049"&gt;450049&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;IL-1 trap is synthesized as a recombinant protein by cultured eukaryotic cells. It is a fusion protein in which the extracellular binding domains of IL-1RI and IL-1RacP have been engineered into a single chain, with two of these chains coupled to the Fc portion of a human IgG to form a dimeric molecule [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="478752"&gt;478752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In the TF1 cell line (human erythroleukemia), IL-1 trap binds IL-1beta with an extremely high affinity (Kd = 1.5 pM) [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;], preventing IL-1beta from interacting with its cell surface receptors and causing it to lose its biological effects. In addition, IL-1 trap binds IL-1alpha with high affinity (Kd = 3 pM) in human MRC5 fibroblasts [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;IL-1 is known to stimulate IL-6 production by human fibroblasts [&lt;ulink linkType="reference" linkID="266429"&gt;266429&lt;/ulink&gt;]. In the MRC5 human fibroblast cell line, IL-1 trap blocked the stimulatory effects of IL-1 on IL-6 production with a high potency (IC50 = 4 pM) [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;]. This was confirmed in vivo, where administration of IL-1beta to mice caused a rapid rise in serum IL-6 levels that peaked after 2 h. Administration of IL-1 trap 24 h prior to IL-1beta dosing completely blocked this IL-6 induction and also blocked the effects of another IL-1beta dose 24 h later. By contrast, a comparable regimen using IL-1ra at similar, or 15-fold higher doses did not block the actions of IL-1beta [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;These effects also translate into therapeutic effects in experimental animal models. In a mouse collagen-induced arthritis model, administration of a mouse version of IL-1 trap (10 or 31 mg/kg, three-times per week) effectively blocked the development of arthritic joints. These doses of IL-1 trap also reduced bone erosion within the hindlimb joints [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The pharmacokinetics of IL-1 trap (3 mg/kg) were investigated in primates. A Cmax of 13.1 microg/ml, a terminal half-life of 67 h and a bioavailability of 70% were observed for IL-1 trap [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I single-dose escalation study of IL-1 trap (n = 20 RA patients in four cohorts), the pharmacokinetics of IL-1 trap were dose dependent. Tmax values ranged from 90 to 120 h and Cmax ranged from 218 to 1896 ng/ml following administration of 50 to 400 mg/kg sc IL-1 trap. Terminal half-life varied from 128 to 182 h [&lt;ulink linkType="reference" linkID="472434"&gt;472434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The IL-1/IL-1 trap complex is washed out of the circulation and tissues and eliminated by phagocytes in a similar manner to other immune complexes [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;The safety and efficacy of IL-1 trap was assessed in a phase Ib, randomized, dose-escalating, double-blind, placebo-controlled trial involving four groups of 15 to 20 patients with active RA. Each group received six weekly doses of IL-1 trap (0, 200, 400 or 800 microg/kg). The American College of Rheumatology (ACR) response rate was used to assess the efficacy of the treatment. The group administered the highest dose experienced the largest improvement. After 6 weeks, an average of 20% improvement (ACR20) in clinical and biological signs of disease activity was achieved by 79% of patients in the 800 microg/kg group compared with 46% of placebo-treated patients. ACR50 was achieved by 49% of the 800-microg/kg group compared with 19% in the placebo group. These results were statistically significant. Circulating levels of C-reactive protein, a marker of inflammation, decreased in a dose-dependent manner in IL-1 trap-treated patients, with an average 20% improvement achieved by 74% of patients in the 800-microg/kg group compared with 36% of placebo-treated patients [&lt;ulink linkType="reference" linkID="435060"&gt;435060&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="450049"&gt;450049&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A multi-center, randomized, placebo-controlled, double-blind phase II trial is currently underway, involving a total of 200 patients with active RA randomized to receive weekly subcutaneous injections of one of three doses of IL-1 trap (25, 50 or 100 mg) or placebo. The treatment period will last 12 weeks and the effect of the treatment will be evaluated for an additional 10 weeks following treatment. The ACR20 response for improvement will be used as a primary endpoint [&lt;ulink linkType="reference" linkID="459031"&gt;459031&lt;/ulink&gt;]. Results from this trial are expected by mid-2003 [&lt;ulink linkType="reference" linkID="476363"&gt;476363&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;No drug-related serious adverse events were reported in the phase I trial. After 6 weeks of treatment, the patients did not develop anti-IL-1 trap antibodies [&lt;ulink linkType="reference" linkID="429356"&gt;429356&lt;/ulink&gt;]. As noted with other biological agents, contraindications include the presence of an active infectious process and a history of allergy to the agent (in this case IL-1 trap) [&lt;ulink linkType="reference" linkID="454821"&gt;454821&lt;/ulink&gt;]. Consistent with the proposed guidelines for treatment with other biological agents, administration of IL-1 trap is unlikely to be recommended in pregnant and breast-feeding patients, or in patients with a history of cancer. Preliminary data obtained in RA patients treated with IL-1ra and &lt;ulink linkType="Drug" linkID="4567"&gt;etanercept&lt;/ulink&gt; (soluble tumor necrosis factor (TNF) receptor p75 coupled to the Fc fragment of human IgG1) indicated that the combination of IL-1 and TNFa inhibitors is associated with a significant increase of superimposed infections. Thus, the administration of IL-1 trap with TNFa inhibitors is not recommended [&lt;ulink linkType="reference" linkID="478763"&gt;478763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="7274"&gt;Anakinra&lt;/ulink&gt; has been on the market in the US for more than a year. In different clinical trials in which &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; was used alone or in combination with other disease-modifying anti-rheumatic drugs (DMARDs), the most frequent side effect was the occurrence of injection site reactions in approximately 70% of patients. Infections are also a concern in therapies which block cytokines that are involved in the innate immune response. The percentage of serious infectious events is slightly higher in patients treated with &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; (2%) than in those receiving a placebo (0.6%). No cases of tuberculosis nor opportunistic infection have, however, been reported so far. The risk of cancer was also not increased by &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;. These results suggest that therapies which aim to block IL-1 are safe [&lt;ulink linkType="reference" linkID="454821"&gt;454821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;IL-1 has been demonstrated to play a major role in the occurrence of articular inflammation and in the development of subsequent joint damage in various in vitro and in vivo models. In clinical trials, &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; was efficacious in controlling the clinical signs of arthritis and the progression of joint damage either alone or in combination with DMARDs. Thus, both experimental and clinical data provide excellent evidence to support the use of IL-1 inhibitors in the treatment of RA.&lt;/para&gt;&lt;para&gt;In a phase I clinical trial, IL-1 trap treatment was well tolerated and was efficacious in improving both the clinical and biological parameters of disease activity. These results and the potential protective effect of IL-1 trap on joint damage should be confirmed by future studies.&lt;/para&gt;&lt;para&gt;IL-1 trap has a strong binding affinity for both IL-1alpha and IL-1beta. The inhibitory effect of IL-1 trap on IL-1-induced IL-6 production in the MRC5 fibroblastic cell line was significantly stronger than that of soluble IL-1RI and IL-1RII, and of &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;. This result is consistent with the weaker binding affinity of IL-1RI and IL-1RII to IL-1 (Kd = 1 to 3 nM and 500 pM, respectively [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;]). Most importantly, although soluble IL-1RI alone binds &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; more tightly than it does with IL-1beta, IL-1 trap binds IL-1beta with a much stronger affinity than &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;. Thus, administration of IL-1 trap should not affect the anti-inflammatory effect of endogenous IL-1ra. The presence of the Fc fraction of human immunoglobulin enhances the circulating half-life of IL-1 trap.&lt;/para&gt;&lt;para&gt;IL-1-targeted therapies, and IL-1 trap in particular, may therefore offer an advantage over existing therapies, although the percentage of patients achieving ACR20 or 50 scores following &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; treatment was not as good as that observed with TNF inhibitors. It is possible that TNFalpha may play a predominant role over IL-1 in the pathogenesis of human RA in contrast with results from collagen-induced arthritis in mice. It is also conceivable, however, that &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; does not completely inhibit the biological effects of IL-1. Indeed, &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; needs to be administered in large molar excess in order to inhibit the binding of IL-1 to its cell surface receptors [&lt;ulink linkType="reference" linkID="454821"&gt;454821&lt;/ulink&gt;]. IL-1 trap was significantly more potent than &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; in inhibiting the effect of IL-1 on IL-6 production in mice injected with recombinant human IL-1beta [&lt;ulink linkType="reference" linkID="478437"&gt;478437&lt;/ulink&gt;]. These results confirm in vitro findings and suggest a possible advantage of IL-1 trap over &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; in the treatment of RA and other IL-1-mediated diseases.&lt;/para&gt;&lt;para&gt;Despite its success in clinical trials, IL-1 trap is attempting to enter a very competitive market of biological agents for the treatment of inflammatory diseases. Since their introduction, TNF inhibitors have gained a large part of this market, in particular for the treatment of RA. Two different TNF inhibitors, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (Remicade) and &lt;ulink linkType="Drug" linkID="4567"&gt;etanercept&lt;/ulink&gt; (Enbrel), are commercially available and a third, &lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt; (Humira; &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="24236"&gt;Cambridge Antibody Technology Group plc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="15872"&gt;Eisai Co Ltd&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="25900"&gt;GTC Biotherapeutics Inc&lt;/ulink&gt;) was launched in the US in January 2003, with a European launch scheduled for mid-2003. As well as &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt;, other inhibitors targeting IL-6 and IL-18 are also currently being investigated in clinical studies. Other therapeutic options including targeting B-cells or T-cells are also being developed. IL-1 trap will have to compete with &lt;ulink linkType="Drug" linkID="7274"&gt;anakinra&lt;/ulink&gt; and other IL-1 inhibitors including soluble IL-1RII, ICE inhibitors and IL-1 signaling inhibitors. However, IL-1 trap may possess some advantages over existing therapies including its longer circulating half-life and its high binding affinity for IL-1.&lt;/para&gt;&lt;para&gt;IL-1 trap provides a novel and interesting approach to the inhibition of IL-1 in the treatment of RA and other IL-1-mediated diseases. It remains to be seen how it will fare against similar strategies aimed at blocking other cytokines and growth factors currently in development.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2008-03-25T00:00:00.000Z</StatusDate><Source id="888998" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2008-03-25T00:00:00.000Z</StatusDate><Source id="888998" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2008-03-25T00:00:00.000Z</StatusDate><Source id="888998" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123466">Kiniksa Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1531">Pericarditis</Indication><StatusDate>2018-12-11T00:00:00.000Z</StatusDate><Source id="2103245" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3244">Familial mediterranean fever</Indication><StatusDate>2013-01-09T00:00:00.000Z</StatusDate><Source id="1356657" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1011051">Neovii Biotech GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2016-09-14T00:00:00.000Z</StatusDate><Source id="2011044" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3244">Familial mediterranean fever</Indication><StatusDate>2018-11-01T00:00:00.000Z</StatusDate><Source id="2089481" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3600">Autoinflammatory disease</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1926124" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2018-11-01T00:00:00.000Z</StatusDate><Source id="2089481" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2013-02-15T00:00:00.000Z</StatusDate><Source id="1393805" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2008-05-14T00:00:00.000Z</StatusDate><Source id="1018320" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2013-02-15T00:00:00.000Z</StatusDate><Source id="1393805" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2013-02-15T00:00:00.000Z</StatusDate><Source id="1393805" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2004-02-27T00:00:00.000Z</StatusDate><Source id="525146" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2005-09-26T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2012-10-24T00:00:00.000Z</StatusDate><Source id="1334180" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2006-03-26T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2887">Polymyalgia rheumatica</Indication><StatusDate>2006-03-26T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2007-05-16T00:00:00.000Z</StatusDate><Source id="645230" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1626">Coronary atherosclerosis</Indication><StatusDate>2008-06-29T00:00:00.000Z</StatusDate><Source id="769590" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2016-09-14T00:00:00.000Z</StatusDate><Source id="2011044" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-02-28T00:00:00.000Z</StatusDate><Source id="1121203" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1121202" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-11-22T00:00:00.000Z</StatusDate><Source id="1242300" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1121202" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1121202" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-02-28T00:00:00.000Z</StatusDate><Source id="1121203" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1121202" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1121202" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2009-10-27T00:00:00.000Z</StatusDate><Source id="1052360" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2009-10-27T00:00:00.000Z</StatusDate><Source id="1052360" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2009-10-27T00:00:00.000Z</StatusDate><Source id="1052360" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2000-12-19T00:00:00.000Z</StatusDate><Source id="394203" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1998-07-06T00:00:00.000Z</StatusDate><Source id="291063" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3244">Familial mediterranean fever</Indication><StatusDate>2016-09-14T00:00:00.000Z</StatusDate><Source id="2011044" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3244">Familial mediterranean fever</Indication><StatusDate>2016-09-14T00:00:00.000Z</StatusDate><Source id="2011044" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123466">Kiniksa Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1531">Pericarditis</Indication><StatusDate>2017-09-25T00:00:00.000Z</StatusDate><Source id="2046748" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2003-03-31T00:00:00.000Z</StatusDate><Source id="483920" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123466">Kiniksa Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1531">Pericarditis</Indication><StatusDate>2018-04-27T00:00:00.000Z</StatusDate><Source id="2046748" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2004-02-27T00:00:00.000Z</StatusDate><Source id="525146" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="586377" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2007-08-01T00:00:00.000Z</StatusDate><Source id="769947" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2007-08-01T00:00:00.000Z</StatusDate><Source id="817982" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2007-06-08T00:00:00.000Z</StatusDate><Source id="803245" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2008-02-27T00:00:00.000Z</StatusDate><Source id="881077" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2007-09-10T00:00:00.000Z</StatusDate><Source id="829048" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2007-11-14T00:00:00.000Z</StatusDate><Source id="1018320" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><StatusDate>2008-09-10T00:00:00.000Z</StatusDate><Source id="943143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1626">Coronary atherosclerosis</Indication><StatusDate>2006-12-29T00:00:00.000Z</StatusDate><Source id="769590" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2004-09-26T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2887">Polymyalgia rheumatica</Indication><StatusDate>2004-09-26T00:00:00.000Z</StatusDate><Source id="616163" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2005-11-16T00:00:00.000Z</StatusDate><Source id="645230" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2008-02-27T00:00:00.000Z</StatusDate><Source id="881077" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2008-09-10T00:00:00.000Z</StatusDate><Source id="943143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3222">Muckle Wells syndrome</Indication><StatusDate>2007-06-08T00:00:00.000Z</StatusDate><Source id="803245" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2008-02-27T00:00:00.000Z</StatusDate><Source id="881077" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2008-09-10T00:00:00.000Z</StatusDate><Source id="943143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19214">Regeneron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3602">Familial cold autoinflammatory syndrome</Indication><StatusDate>2007-06-08T00:00:00.000Z</StatusDate><Source id="803245" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><AwardedIndication>Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-06-08T00:00:00.000Z</MileStoneDate><Source id="803245" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3600">Autoinflammatory disease</Indication><AwardedIndication>Treatment of deficiency of interleukin-1 receptor antagonist (DIRA)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-05-09T00:00:00.000Z</MileStoneDate><Source id="1926124" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3244">Familial mediterranean fever</Indication><AwardedIndication>Treatment of familial Mediterranean fever</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-01-09T00:00:00.000Z</MileStoneDate><Source id="1356657" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><AwardedIndication>Treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-07-10T00:00:00.000Z</MileStoneDate><Source id="817982" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><AwardedIndication>Treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2007-05-31T00:00:00.000Z</MileStoneDate><Source id="801439" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3003">Juvenile rheumatoid arthritis</Indication><AwardedIndication>Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2005-04-04T00:00:00.000Z</MileStoneDate><Source id="670403" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19214">Regeneron Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3601">Cryopyrin associated periodic syndrome</Indication><AwardedIndication>Treatment of CIAS1-Associated Periodic Syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2004-12-20T00:00:00.000Z</MileStoneDate><Source id="586377" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03142"><Name>Interleukin-1 alpha ligand</Name><SwissprotNumbers><Swissprot>O46612</Swissprot><Swissprot>O46613</Swissprot><Swissprot>P01582</Swissprot><Swissprot>P01583</Swissprot><Swissprot>P04822</Swissprot><Swissprot>P08831</Swissprot><Swissprot>P16598</Swissprot><Swissprot>P18430</Swissprot><Swissprot>P46647</Swissprot><Swissprot>P48089</Swissprot><Swissprot>P79161</Swissprot><Swissprot>P79340</Swissprot><Swissprot>Q28385</Swissprot><Swissprot>Q28579</Swissprot><Swissprot>Q60480</Swissprot><Swissprot>Q865X7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03143"><Name>Interleukin-1 beta ligand</Name><SwissprotNumbers><Swissprot>P01584</Swissprot><Swissprot>P09428</Swissprot><Swissprot>P10749</Swissprot><Swissprot>P14628</Swissprot><Swissprot>P21621</Swissprot><Swissprot>P26889</Swissprot><Swissprot>P41687</Swissprot><Swissprot>P46648</Swissprot><Swissprot>P48090</Swissprot><Swissprot>P51493</Swissprot><Swissprot>P51745</Swissprot><Swissprot>P79162</Swissprot><Swissprot>P79182</Swissprot><Swissprot>Q28292</Swissprot><Swissprot>Q28386</Swissprot><Swissprot>Q63264</Swissprot><Swissprot>Q6R2X3</Swissprot><Swissprot>Q865X8</Swissprot><Swissprot>Q8WNR2</Swissprot><Swissprot>Q9WVG1</Swissprot><Swissprot>Q9XS77</Swissprot><Swissprot>Q9YGD3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2147780" linkType="reference" linkID="2147780"&gt;2147780&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1123466">Kiniksa Pharmaceuticals Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19214">Regeneron Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="21388">Neopharm Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><Deals><Deal id="112006" title="Novartis and Regeneron to develop and commercialize IL-1 antagonists "/><Deal id="154950" title="Regeneron to license Amgen's IP rights to develop and commercialize Interleukin-1 Trap    "/><Deal id="245894" title="Neovii to develop and commercialize Regeneron's Arcalyst for periodic fever syndromes worldwide excluding the US and Japan"/><Deal id="247708" title="Kiniksa to develop and commercialize Regeneron Pharmaceuticals' rilonacept worldwide excluding Israel, Egypt, Turkey and select countries in MENA "/></Deals><PatentFamilies><PatentFamily id="1099527" number="WO-2004098596" title="Composition comprising roflumilast and IL-1 Trap"/><PatentFamily id="1467583" number="WO-2005117945" title="Methods of using IL-1 antagonists to treat autoinflammatory disease"/><PatentFamily id="1597647" number="WO-2009053098" title="Inhibitors of caspase I-dependent cytokines in the treatment of neurodegenerative disorders"/><PatentFamily id="1608673" number="US-20050129685" title="Use of IL-1 blockers to prevent corneal inflammation and neovascularization"/><PatentFamily id="1831112" number="WO-2004039951" title="IL-1 receptor based antagonists and methods of making and using"/><PatentFamily id="1899644" number="WO-2006084145" title="Methods of using il-1 antagonists to reduce c-reactive protein"/><PatentFamily id="2136699" number="WO-2004100987" title="Methods of using IL-1 antagonists to treat neointimal hyperplasia"/><PatentFamily id="2170276" number="WO-00018932" title="Receptor based antagonists and methods of making and using"/><PatentFamily id="2327155" number="WO-2006076673" title="Methods of treating obesity with combination therapeutics"/><PatentFamily id="2365479" number="WO-2008051496" title="Use of IL-1 antagonists to treat gout and pseudogout"/><PatentFamily id="2498016" number="WO-2013045404" title="Inhibition of the effect of interleukin 1 beta in order to treat endometriosis"/><PatentFamily id="275492" number="US-20100233168" title="Rationale for IL-1 β targeted therapy in sickle cell disease for ischemia-reperfusion induced complications"/><PatentFamily id="2836004" number="WO-2014194166" title="Methods of using IL-1 antagonists to treat Alzheimer's disease"/><PatentFamily id="2915310" number="WO-2015051279" title="CXCR4 up- and down-regulation for treatment of diseases or disorders"/><PatentFamily id="3107102" number="WO-2016005747" title="Treatment of lysosomal disorders (IL-1 antagonists)"/><PatentFamily id="327535" number="WO-2004098605" title="Pharmaceutical composition comprising a PDE4 inhibitor and IL-1 Trap"/><PatentFamily id="3808339" number="WO-2017168296" title="A process for purification of Fc-fusion proteins"/><PatentFamily id="4344674" number="WO-2019010191" title="Cell culture process for making a glycoprotein"/><PatentFamily id="4455672" number="WO-2019067639" title="Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein"/><PatentFamily id="585733" number="WO-2006023665" title="IL-1 antagonist formulations"/><PatentFamily id="615906" number="WO-09511303" title="CNTF family antagonists."/><PatentFamily id="821904" number="WO-2012121679" title="Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>13</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agency For Science Technology &amp; Research" id="1006569"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National University Hospital" id="1026299"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Navya Biologicals Pvt Ltd" id="1058952"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="bluebird bio Inc" id="16284"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="H Lundbeck A/S" id="17900"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev" id="17962"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Regeneron Pharmaceuticals Inc" id="19214"/><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Oxford" id="22182"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sidney Kimmel Cancer Center" id="22971"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Drexel University" id="23139"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Colorado System" id="25520"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>